Filing Flows › Anteris Technologies Global (AVR) › Recalls, complaints & regulation

Anteris Technologies Global (AVR): clinical trials

Anteris Technologies Global (AVR) beyond its filings: 4 active clinical trials.

Anteris Technologies Global's latest quarter

Anteris Technologies Global, Q2 2026: revenue $1.0M (+63% year over year), net loss $28.8M, operating cash flow −$20.8M. The chart follows the revenue to costs, profit and cash.

Questions

How many clinical trials does Anteris Technologies Global have?

4 active studies on ClinicalTrials.gov, 0 in phase 3.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.